Skip to content

Status
Not yet recruiting
Phases
Phase 3
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2016-002786-62-FR
Enrollment
272
Registered
2017-05-16
Start date
2017-04-14
Completion date
Unknown
Last updated
2020-02-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

MedDRA version: 20.0 Level: PT Classification code 10015087 Term: Episiotomy System Organ Class: 10042613 - Surgical and medical procedures

Interventions

Trade Name: Ropivacaïne 7,5 mg/mL Product Name: ROPIVACAINE Pharmaceutical Form: Solution for injection INN or Proposed INN: ROPIVACAINE HYDROCHLORIDE

Sponsors

Centre Hospitalier Départemental Vendée
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 272 F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Main Objective: ;Secondary Objective: ;Primary end point(s):

Countries

France

Contacts

Public ContactAUZANNEAU Lucie

Centre Hospitalier Départemental Vendée

lucie.auzanneau@chd-vendee.fr330251446380

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 27, 2026